Revolution Medicines, Inc. RVMD
Revolution Medicines, Inc. (Nasdaq: RVMD) is an oncology drug developer. Its lead program, RASONQUE (daraxonrasib), is in Phase 3 for metastatic pancreatic adenocarcinoma (PDAC). Its next catalyst on record is RASolve 301 (RASONQUE): Complete enrollment (November 2026).
Upcoming catalysts
- November 2026RASolve 301 (RASONQUE) — Complete enrollment
We currently expect to complete enrollment in RASolve 301 by the end of November 2026, to enable an expected clinical readout in 2027
Next further out: RASolute 303 (RASONQUE) — Complete global enrollment (H1 2027). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| RASONQUE (daraxonrasib) | metastatic pancreatic adenocarcinoma | small molecule | Approved |
| zoldonrasib (RMC-9805) | KRAS G12D-mutated NSCLC and PDAC | small molecule | Phase 3 |
| elironrasib (RMC-6291) | KRAS G12C-mutated NSCLC | small molecule | Phase 3 |
| RMC-5127 | RAS G12V-mutated cancers | small molecule | Phase 1 |
| RMC-0708 | RAS Q61H-mutated cancers | small molecule | Pre-clinical |
| RMC-8839 | RAS G13C-mutated cancers | small molecule | Pre-clinical |
Recent results and decisions
- Nov 4, 2026started RASolute 309 Phase 3 trial evaluating daraxonrasib plus zoldonrasib in treatment-naïve metastatic RAS G12D pancreatic cancer has begun treating patients.
The company announced it has begun treating patients in RASolute 309, the global Phase 3 trial evaluating the novel RAS(ON) inhibitor doublet of daraxonrasib plus zoldonrasib in patients with treatment-naïve metastatic RAS G12D pancreatic cancer.
Filing - Nov 4, 2026started RASolve 307 Phase 3 trial evaluating elironrasib with pembrolizumab and platinum doublet chemotherapy in treatment-naïve metastatic RAS G12C NSCLC has been initiated.
The company initiated RASolve 307, a global Phase 3 trial in patients with treatment-naïve metastatic RAS G12C NSCLC. The trial is evaluating elironrasib, the company's oral, RAS(ON) G12C-selective covalent inhibitor, in combination with pembrolizumab and platinum doublet chemotherapy.
Filing - Oct 31, 2026adcomm positive CHMP adopted a positive opinion recommending approval of daraxonrasib for treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy in the European Union.
In October, the company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion recommending approval of daraxonrasib as a monotherapy indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma
Filing
7 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Astrazeneca PLC AZN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Genmab A/S GMAB
- BioNTech SE BNTX
- Guardant Health, Inc. GH
- Exelixis, Inc. EXEL
- Summit Therapeutics Inc. SMMT
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.